162 related articles for article (PubMed ID: 15026802)
21. Genetic alterations distinguish different types of ovarian tumors.
Pieretti M; Cavalieri C; Conway PS; Gallion HH; Powell DE; Turker MS
Int J Cancer; 1995 Dec; 64(6):434-40. PubMed ID: 8550247
[TBL] [Abstract][Full Text] [Related]
22. Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
Wang W; Li YF; Sun XW; Chen G; Zhan YQ; Huang CY; Wan DS; Pan ZZ; Zhou ZW
Chin J Cancer; 2010 Aug; 29(8):761-7. PubMed ID: 20663324
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas].
Petrović B; Perović M; Novaković I; Atanacković J; Popović B; Luković L; Petković S
Vojnosanit Pregl; 2006 Sep; 63(9):813-8. PubMed ID: 17039893
[TBL] [Abstract][Full Text] [Related]
24. Parkin gene alterations in ovarian carcinoma from northern Indian population.
Mehdi SJ; Ali A; Rizvi MM
Pathol Oncol Res; 2011 Sep; 17(3):579-86. PubMed ID: 21221875
[TBL] [Abstract][Full Text] [Related]
25. Low-malignant potential epithelial tumors of the ovary: a clinicopathological study.
Hassan E; Koumantaki Y; Stefanaki K; Matalliotakis I; Koumantakis E
Eur J Gynaecol Oncol; 1998; 19(2):170-2. PubMed ID: 9611060
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
27. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity.
Zborovskaya I; Gasparian A; Karseladze A; Elcheva I; Trofimova E; Driouch K; Trassard M; Tatosyan A; Lidereau R
Int J Cancer; 1999 Sep; 82(6):822-6. PubMed ID: 10446448
[TBL] [Abstract][Full Text] [Related]
28. No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms.
Shih YC; Kerr J; Hurst TG; Khoo SK; Ward BG; Chenevix-Trench G
Gynecol Oncol; 1998 Jun; 69(3):210-3. PubMed ID: 9648589
[TBL] [Abstract][Full Text] [Related]
29. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations.
Chenevix-Trench G; Kerr J; Hurst T; Shih YC; Purdie D; Bergman L; Friedlander M; Sanderson B; Zournazi A; Coombs T; Leary JA; Crawford E; Shelling AN; Cooke I; Ganesan TS; Searle J; Choi C; Barrett JC; Khoo SK; Ward B
Genes Chromosomes Cancer; 1997 Feb; 18(2):75-83. PubMed ID: 9115967
[TBL] [Abstract][Full Text] [Related]
30. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
31. Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors?
Tsuji T; Catasus L; Prat J
Hum Pathol; 2005 Jul; 36(7):792-6. PubMed ID: 16084949
[TBL] [Abstract][Full Text] [Related]
32. A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas.
Colitti CV; Rodabaugh KJ; Welch WR; Berkowitz RS; Mok SC
Oncogene; 1998 Jan; 16(4):555-9. PubMed ID: 9484846
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas.
Plisiecka-Hałasa J; Dansonka-Mieszkowska A; Kraszewska E; Dańska-Bidzińska A; Kupryjańczyk J
Anticancer Res; 2008; 28(2A):989-96. PubMed ID: 18507046
[TBL] [Abstract][Full Text] [Related]
34. Matching maternal isodisomy in mucinous carcinomas and associated ovarian teratomas provides evidence of germ cell derivation for some mucinous ovarian tumors.
Kerr SE; Flotte AB; McFalls MJ; Vrana JA; Halling KC; Bell DA
Am J Surg Pathol; 2013 Aug; 37(8):1229-35. PubMed ID: 23774174
[TBL] [Abstract][Full Text] [Related]
35. Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region.
Kanazawa T; Watanabe T; Kazama S; Tada T; Koketsu S; Nagawa H
Int J Cancer; 2002 Nov; 102(3):225-9. PubMed ID: 12397640
[TBL] [Abstract][Full Text] [Related]
36. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis.
Watson RH; Neville PJ; Roy WJ; Hitchcock A; Campbell IG
Oncogene; 1998 Jul; 17(2):207-12. PubMed ID: 9674705
[TBL] [Abstract][Full Text] [Related]
38. Fractional allelic loss in gastric carcinoma correlates with growth patterns.
Choi SW; Park SW; Lee KY; Kim KM; Chung YJ; Rhyu MG
Oncogene; 1998 Nov; 17(20):2655-9. PubMed ID: 9840929
[TBL] [Abstract][Full Text] [Related]
39. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
[TBL] [Abstract][Full Text] [Related]
40. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Villa A; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Lombardi AV; Sorio R; Mangili G; Priolo D; Magni G; Morabito A
BMC Cancer; 2008 Sep; 8():252. PubMed ID: 18761742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
